CD274 and esophageal squamous cell carcinoma: The survival benefit was more prominent in patients with ESCC and high PD-L1 expression (CPS ≥ 10) as reported in the KEYNOTE-181 study (mOS = 10.3 on IO vs 6.7 months on chemotherapy; HR = 0.64; 95% CI = 0.46 to 0.90) (17) and RATIONALE-302 (mOS =10.3 on IO vs 6.8 months on chemotherapy; HR = 0.54, 95% CI = 0.36 to 0.79).